Drug Discovery Programmes of Cancer Research UK and Cancer Research Technology showcased at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting in Boston
17th November, 2009 ---- Cancer Research Technology (CRT) is hosting thirty-five industrial scientists, representing the research and drug discovery functions of eighteen of the world’s top pharmaceutical and biotechnology companies, during the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting in Boston. The objective of the “Science & Seafood” luncheon is to introduce scientific leaders responsible for companies' cancer drug discovery and development to Cancer Research UK and Cancer Research Technology's drug discovery programmes. The event features presentations by two of the charity's leading translational scientists, Professors Paul Workman and Peter Parker.
Cancer Research UK - the world's largest independent organisation dedicated to cancer research, invested £303 million last year (2008/09) on research.
|
